NeoGenomics delivers excellence in cancer diagnostics, information services, and pharmacological services to its customers — oncologists and pathologists, pharma companies, and academic research centers — supporting their endeavors to provide patients living with cancer the best care and outcomes.
For nearly 20 years, NeoGenomics laboratories have developed and delivered diagnostic tests and provided clinical trial support, focusing specifically on cancer. Our company is made up of experts located worldwide who work together with cancer care teams to provide life-saving insights.
Precision oncology is an exciting advancement and a vital part of cancer care today. While our testing menu continues to offer traditional testing methods, we are constantly expanding and adding more targeted, more personalized tests as they are discovered, validated, and developed — just like the RaDaR MRD — to meet the needs of your patients.
We have national and international reach through our interconnected CAP-accredited, CLIA-certified labs located in the US and abroad. We are also very proud to offer blood sample collection in the US through our nationwide mobile phlebotomy network at no cost to you or your patients.
NeoGenomics delivers excellence in cancer care through its world-class testing services and dedicated experts who are committed to helping you find answers.
We are proud of the life-changing support we can provide to hospitals, private pathology labs, office-based oncologists, contract research groups, pharma research and development departments, and academic institutions. Our experts work every day to explore new clinical data and emerging technologies to offer the most accurate and insightful tests possible.
GO FURTHER INTO OUR HISTORY, OUR CORPORATE STEWARDSHIP, INVESTOR OPPORTUNITIES, AND CAREERS
CAP = College of American Pathologists; CLIA = Clinical Laboratory Improvement Amendments.
Contact us to order a RaDaR test.